^
Phase 1
National Cancer Institute (NCI)
Recruiting
Last update posted :
06/30/2022
Initiation :
03/05/2021
Primary completion :
03/31/2026
Completion :
03/31/2026
CD4
|
HER-2 positive • HER-2 amplification • HER-2 expression
|
Enhertu (fam-trastuzumab deruxtecan-nxki) • ceralasertib (AZD6738) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
06/30/2022
Initiation :
01/13/2017
Primary completion :
10/31/2023
Completion :
10/31/2023
CD4
|
PD-L1 overexpression • PD-L1 amplification
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • CMAB 819 (nivolumab biosimilar) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
Hoffmann-La Roche
Recruiting
Last update posted :
06/28/2022
Initiation :
11/19/2015
Primary completion :
12/31/2024
Completion :
04/01/2025
NTRK1 • ROS1 • NTRK3 • NTRK2
|
ALK rearrangement • ROS1 rearrangement
|
Xalkori (crizotinib) • Rozlytrek (entrectinib) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
Merck Sharp & Dohme LLC
Recruiting
Last update posted :
06/08/2022
Initiation :
12/18/2015
Primary completion :
06/18/2026
Completion :
06/18/2026
TMB • MSI
|
TMB-H • MSI-H/dMMR
|
Keytruda (pembrolizumab) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
NRG Oncology
Not yet recruiting
Last update posted :
06/07/2022
Initiation :
11/10/2022
Primary completion :
07/31/2028
Completion :
07/31/2028
HER-2
|
HER-2 positive • HER-2 amplification
|
Herceptin (trastuzumab) • docetaxel • Kadcyla (ado-trastuzumab emtansine) • Trazimera (trastuzumab biosimilar) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
Janssen Pharmaceutical K.K.
Active, not recruiting
Last update posted :
05/20/2022
Initiation :
04/07/2020
Primary completion :
06/09/2021
Completion :
11/22/2022
AR
|
AR positive • AR expression
|
Erleada (apalutamide) • goserelin acetate • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
University of Chicago
Recruiting
Last update posted :
04/14/2022
Initiation :
03/26/2018
Primary completion :
09/01/2022
Completion :
09/01/2022
PD-L1
|
Keytruda (pembrolizumab) • docetaxel • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1
Xencor, Inc.
Recruiting
Last update posted :
04/11/2022
Initiation :
07/10/2018
Primary completion :
11/30/2022
Completion :
02/28/2023
HER-2 • ER • PGR • MSI
|
MSI-H/dMMR • HER-2 negative
|
vudalimab (XmAb717) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
Mayo Clinic
Recruiting
Last update posted :
03/29/2022
Initiation :
07/23/2021
Primary completion :
06/03/2025
Completion :
06/03/2026
PD-L1
|
Keytruda (pembrolizumab) • pemetrexed • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
Manish Patel
Recruiting
Last update posted :
02/24/2022
Initiation :
05/30/2019
Primary completion :
01/01/2023
Completion :
01/01/2024
AR
|
AR positive
|
Keytruda (pembrolizumab) • goserelin acetate • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
Actuate Therapeutics Inc.
Withdrawn
Last update posted :
02/22/2022
Initiation :
12/18/2030
Primary completion :
06/18/2033
Completion :
06/18/2034
BCL2
|
carboplatin • elraglusib (9-ING-41) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1
Baylor College of Medicine
Recruiting
Last update posted :
02/21/2022
Initiation :
12/14/2020
Primary completion :
12/30/2024
Completion :
12/30/2038
HER-2
|
HER-2 positive
|
Invega Sustenna (paliperidone palmitate extended-release 1-month injection) • TT16
Phase 1/2
Klus Pharma Inc.
Active, not recruiting
Last update posted :
02/15/2022
Initiation :
07/16/2018
Primary completion :
04/01/2022
Completion :
12/01/2022
HER-2
|
HER-2 positive • HER-2 expression
|
A166 • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
UNICANCER
Completed
Last update posted :
01/11/2022
Initiation :
03/24/2017
Primary completion :
01/01/2019
Completion :
10/20/2021
PD-L1 • PD-L2
|
TILs
|
Opdivo (nivolumab) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
Samsung Medical Center
Active, not recruiting
Last update posted :
01/04/2022
Initiation :
09/20/2018
Primary completion :
09/01/2022
Completion :
08/01/2023
HER-2
|
HER-2 positive
|
Herzuma (trastuzumab biosimilar) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
Dana-Farber Cancer Institute
Recruiting
Last update posted :
12/28/2021
Initiation :
12/24/2020
Primary completion :
02/01/2025
Completion :
02/01/2026
HER-2
|
HER-2 positive • HER-2 amplification • HER-2 expression
|
cisplatin • carboplatin • Kadcyla (ado-trastuzumab emtansine) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
Universitair Ziekenhuis Brussel
Recruiting
Last update posted :
12/20/2021
Initiation :
04/01/2019
Primary completion :
11/01/2024
Completion :
12/01/2024
HER-2
|
HER-2 expression • HER-2-H
|
Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1/2
University of Chicago
Completed
Last update posted :
10/05/2021
Initiation :
05/01/2013
Primary completion :
04/01/2018
Completion :
09/01/2020
EGFR
|
Erbitux (cetuximab) • cisplatin • buparlisib (AN2025)
Phase N/A
Amina Fouad Farag
Completed
Last update posted :
09/01/2021
Initiation :
08/06/2018
Primary completion :
02/03/2019
Completion :
02/03/2021
CD24
|
CD24 expression
|
Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
Memorial Sloan Kettering Cancer Center
Active, not recruiting
Last update posted :
06/02/2021
Initiation :
05/26/2017
Primary completion :
05/01/2022
Completion :
05/01/2022
AR
|
Opdivo (nivolumab) • Yervoy (ipilimumab)
Phase N/A
Radboud University
Recruiting
Last update posted :
04/09/2021
Initiation :
01/14/2020
Primary completion :
01/01/2022
Completion :
01/01/2023
AR • FOLH1
|
AR positive • FOLH1 expression
|
Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase N/A
Cairo University
Recruiting
Last update posted :
07/21/2020
Initiation :
01/12/2019
Primary completion :
09/01/2021
Completion :
12/01/2021
MYB
|
Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1
National Cancer Institute (NCI)
Completed
Last update posted :
03/13/2020
Initiation :
02/10/2011
Primary completion :
01/29/2014
Completion :
01/29/2014
EGFR • KRAS
|
KRAS wild-type • RAS wild-type
|
Erbitux (cetuximab) • lenalidomide • KL 140 (cetuximab biosimilar)
Phase 2
University Health Network, Toronto
Completed
Last update posted :
02/15/2019
Initiation :
07/01/2002
Primary completion :
01/01/2004
Completion :
01/01/2005
KIT
|
KIT positive
|
imatinib
Phase 2
National Cancer Institute (NCI)
Completed
Last update posted :
04/20/2018
Initiation :
03/16/2009
Primary completion :
01/30/2013
KIT
|
KIT expression • KIT overexpression
|
dasatinib
Phase 2
Fox Chase Cancer Center
Completed
Last update posted :
02/26/2018
Initiation :
02/16/2011
Primary completion :
04/07/2015
Completion :
10/03/2017
EGFR
|
Erbitux (cetuximab) • erlotinib • carboplatin • paclitaxel
Phase 2
National Cancer Institute (NCI)
Completed
Last update posted :
04/18/2017
Initiation :
09/01/2004
Primary completion :
02/01/2009
EGFR • HER-2
|
HER-2 expression • EGFR expression
|
lapatinib
Phase 1
Fox Chase Cancer Center
Withdrawn
Last update posted :
03/03/2016
Initiation :
04/01/2011
Primary completion :
05/01/2011
Completion :
05/01/2011
EGFR • HIF1A
|
erlotinib • everolimus
Phase 1
University of Washington
Completed
Last update posted :
03/05/2015
Initiation :
06/01/2011
Primary completion :
06/01/2014
EGFR • TLR8
|
Erbitux (cetuximab) • motolimod (VTX 2337)
Phase 1/2
National Cancer Institute (NCI)
Completed
Last update posted :
06/11/2014
Initiation :
01/01/2005
Primary completion :
10/01/2007
Completion :
05/01/2008
IL2
|
Avastin (bevacizumab) • Erbitux (cetuximab) • erlotinib • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1
National Cancer Institute (NCI)
Completed
Last update posted :
09/30/2013
Initiation :
12/01/2001
Primary completion :
01/01/2011
HER-2 • ER • PGR
|
ER negative • PGR negative
|
irinotecan • 7-Hydroxystaurosporine (UCN-01)
Phase 1
National Cancer Institute (NCI)
Completed
Last update posted :
02/28/2013
Initiation :
08/01/1999
Primary completion :
02/01/2009
HER-2
|
HER-2 overexpression
|
Herceptin (trastuzumab) • carboplatin • albumin-bound paclitaxel
Phase 1
National Cancer Institute (NCI)
Completed
Last update posted :
01/25/2013
Initiation :
11/01/2001
Primary completion :
11/01/2005
CEACAM5
|
CEACAM5 expression
|
Leukine (sargramostim)
Phase 1
National Cancer Institute (NCI)
Completed
Last update posted :
01/16/2013
Initiation :
12/01/2001
Primary completion :
07/01/2007
EGFR
|
EGFR positive
|
erlotinib
Phase 1
Fox Chase Cancer Center
Completed
Last update posted :
07/11/2012
Initiation :
11/01/2008
Primary completion :
07/01/2011
Completion :
07/01/2011
CEACAM5
|
Erbitux (cetuximab) • everolimus